Volume 48, Issue 5 , Pages 511-518, May 2009
Clinical Responses to Atomoxetine in Attention-Deficit/Hyperactivity Disorder: The Integrated Data Exploratory Analysis (IDEA) Study
To access this article, please choose from the options below
Funding for this research was provided by Eli Lilly and Company.The authors thank Stephen W. Gutkin of Rete Biomedical Communications for assistance in manuscript preparation.Clinical trials registration information—Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed Strattera. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00486122. Results of the other studies analyzed in the Integrated Data Exploratory Analysis study are posted at www.clinicalstudyresults.org, ID numbers 5670, 7972, 2746, 1585, 1586, and 3468, and www.lillytrials.com.
PII: S0890-8567(09)60068-X
doi:10.1097/CHI.0b013e31819c55b2
© 2009 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.
Volume 48, Issue 5 , Pages 511-518, May 2009
